Publication: DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients.
Loading...
Identifiers
Date
2019
Authors
Hidalgo-Tenorio, Carmen
Cortés, Luis López
Gutiérrez, Alicia
Santos, Jesús
Omar, Mohamed
Gálvez, Carmen
Sequera, Sergio
Jesús, Samantha Eisabeth De
Téllez, Franciso
Fernández, Elisa
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Metrics
Export
Abstract
Dolutegravir (DTG) has shown effectiveness in combination with rilpivirine in with experience of antiretroviral therapy (ART) and with 3TC in naïve patients (GEMINI trial). The main objectives of this real-life study were to analyze the effectiveness and safety of 3TC plus DTG in virologically suppressed HIV-1 patients and to conduct a pharmacoeconomic analysis.We conducted an observational, retrospective and multicenter study of HIV+ patients pretreated for at least 6 months with ART that was then simplified to 3TC + DTG for any reason. We gathered data on viral loads (VLs) during exposure to the DT, calculating the rate with VL
Description
MeSH Terms
Adult
Anti-HIV Agents
CD4 Lymphocyte Count
Cost-Benefit Analysis
Drug Therapy, Combination
Economics, Pharmaceutical
Fees, Pharmaceutical
Female
HIV Infections
HIV-1
Heterocyclic Compounds, 3-Ring
Humans
Lamivudine
Male
Middle Aged
Oxazines
Piperazines
Pyridones
Retrospective Studies
Viral Load
Anti-HIV Agents
CD4 Lymphocyte Count
Cost-Benefit Analysis
Drug Therapy, Combination
Economics, Pharmaceutical
Fees, Pharmaceutical
Female
HIV Infections
HIV-1
Heterocyclic Compounds, 3-Ring
Humans
Lamivudine
Male
Middle Aged
Oxazines
Piperazines
Pyridones
Retrospective Studies
Viral Load